The Novel Small Molecule BTB Inhibits Pro-Fibrotic Fibroblast Behavior though Inhibition of RhoA Activity
| Autor: | Ashley R. Rackow, David J. Nagel, Gregory Zapas, Ryan S. Clough, Patricia J. Sime, R. Matthew Kottmann |
|---|---|
| Rok vydání: | 2022 |
| Předmět: |
Organic Chemistry
Cell Differentiation General Medicine Fibroblasts Fibrosis Catalysis Idiopathic Pulmonary Fibrosis Computer Science Applications Inorganic Chemistry pulmonary fibrosis lung GPR65 fibroblast GPCR non-canonical TGFβ signaling Lactates Humans Physical and Theoretical Chemistry Protons Myofibroblasts rhoA GTP-Binding Protein Molecular Biology Lung Spectroscopy |
| Zdroj: | International Journal of Molecular Sciences; Volume 23; Issue 19; Pages: 11946 |
| ISSN: | 1422-0067 |
| Popis: | Idiopathic pulmonary fibrosis (IPF) is a progressive, chronic, interstitial lung disease with a poor prognosis. Although specific anti-fibrotic medications are now available, the median survival time following diagnosis remains very low, and new therapies are urgently needed. To uncover novel therapeutic targets, we examined how biochemical properties of the fibrotic lung are different from the healthy lung. Previous work identified lactate as a metabolite that is upregulated in IPF lung tissue. Importantly, inhibition of the enzyme responsible for lactate production prevents fibrosis in vivo. Further studies revealed that fibrotic lesions of the lung experience a significant decline in tissue pH, likely due to the overproduction of lactate. It is not entirely clear how cells in the lung respond to changes in extracellular pH, but a family of proton sensing G-protein coupled receptors has been shown to be activated by reductions in extracellular pH. This work examines the expression profiles of proton sensing GPCRs in non-fibrotic and IPF-derived primary human lung fibroblasts. We identify TDAG8 as a proton sensing GPCR that is upregulated in IPF fibroblasts and that knockdown of TDAG8 dampens myofibroblast differentiation. To our surprise, BTB, a proposed positive allosteric modulator of TDAG8, inhibits myofibroblast differentiation. Our data suggest that BTB does not require TDAG8 to inhibit myofibroblast differentiation, but rather inhibits myofibroblast differentiation through suppression of RhoA mediated signaling. Our work highlights the therapeutic potential of BTB as an anti-fibrotic treatment and expands upon the importance of RhoA-mediated signaling pathways in the context of myofibroblast differentiation. Furthermore, this works also suggests that TDAG8 inhibition may have therapeutic relevance in the treatment of IPF. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|